Cytek Biosciences to Participate in Upcoming Evercore and Piper Sandler Healthcare Conferences
Cytek Biosciences, Inc. (Nasdaq: CTKB) announced its participation in the Evercore 9th Annual Healthcare Conference on December 1, 2026, and the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026. CEO Wenbin Jiang and CFO William McCombe will engage in investor meetings and a fireside chat, with a webcast available for the Piper Sandler event. The company, known for its Full Spectrum Profiling™ technology, aims to enhance investor visibility and provide insights into its strategic direction.
A manager reports 8 million Cytek Biosciences (CTKB) shares held for client accounts.
Boston Partners reported beneficial ownership of 8,002,638 common shares of Cytek Biosciences (CTKB), representing 6.16% of the class, as of September 30, 2026. These shares are held for discretionary client accounts, with Boston Partners exercising sole voting power over 6,503,524 shares and sole dispositive power over all 8,002,638 shares. The disclosure was made in an amended Schedule 13G/A SEC filing.
Form 4 Cytek Biosciences Inc: Ilan Feuchtwang (Chief Legal Officer, Secretary) For: 9 November
This article reports on a Form 4 filing for Cytek Biosciences Inc, indicating that Ilan Feuchtwang, the Chief Legal Officer and Secretary, made a transaction on November 9th. The filing is a standard disclosure of changes in company insider ownership.
What Cytek Biosciences Holders Got Right
Cytek Biosciences (NasdaqGS:CTKB) shareholders have seen a 20.4% return over the past year, driven by a mixed Q3 2026 performance with increased revenue but also a deeper loss and softer net margin. The article explores the contrasting bullish and bearish perspectives on the company's future, focusing on recurring revenue from cloud tools and reagents versus rising costs and competition. Despite the price reflecting a positive outlook, the analysis suggests the current valuation may not align with cautious narratives regarding profitability and operational strain.
Cytek Biosciences, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:CTKB) 2026-11-09
Cytek Biosciences, Inc. has published its slide deck in conjunction with its 2026 Q3 earnings call. This presentation provides details related to their financial results for the third quarter of 2026. The article was written by SA Transcripts, Seeking Alpha's team dedicated to publishing earnings call transcripts.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Analysts Are Pretty Bullish On The Stock After Recent Results
Cytek Biosciences (NASDAQ:CTKB) recently released its quarterly results, showing revenues in line with expectations at US$53m and narrower statutory losses of US$0.05 per share. Analysts have maintained their revenue forecasts for 2027 at US$222.8m but have become more optimistic about loss per share, predicting a significant reduction to US$0.25. The average price target for the stock has increased by 11% to US$6.17, suggesting that the expected reduction in losses is viewed positively for the company's valuation.
Piper Sandler Remains a Buy on Cytek Biosciences (CTKB)
Piper Sandler analyst David Westenberg reiterated a Buy rating on Cytek Biosciences (CTKB) with a $7.50 price target. Westenberg, who covers the Healthcare sector, has an average return of 18.9% and a 57.89% success rate. The company recently reported quarterly revenue of $48.14 million and a GAAP net loss of $12.16 million.
A lab tool takes about 40% less time to read plate samples than earlier versions. It wins a drug discovery award.
Cytek Biosciences' Aurora Evo system has been honored with the Drug Discovery Innovation of the Year award at the 2026 BioTech Breakthrough Awards. This system significantly reduces plate-well acquisition time by approximately 40% compared to previous generations and includes automated features, enhancing efficiency and data consistency for complex research workflows. The company is also developing the platform for automated sample processing using robotic arms, further streamlining drug discovery efforts.
Cytek Biosciences Q3 Earnings Call Highlights
Cytek Biosciences reported Q3 2026 revenue of $53.2 million, a 2% increase year-over-year, driven by strong U.S. demand and high-end instrument sales, despite weakness in Asia-Pacific. The company narrowed its full-year revenue guidance and expects adjusted EBITDA to be near break-even. Gross margins improved due to manufacturing transfer and lower costs, though the net loss widened primarily due to increased legal expenses related to patent litigation.
Cytek Biosciences Q3FY26 Results: Revenue up 2% to $53.2 million
Cytek Biosciences reported a 2% year-over-year revenue increase to $53.2 million for Q3 FY26, primarily driven by strong U.S. performance and high-end instrument placements. Despite gross margin expansion to 59% due to manufacturing shifts to Singapore, the net loss widened to $6.1 million, mainly impacted by lower tax benefits and increased legal expenses. The company maintained its full-year revenue guidance midpoint at $208-$211 million, anticipating reduced legal costs in Q4.
Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates
Cytek Biosciences, Inc. (CTKB) reported a Q3 loss of $0.05 per share, surpassing the Zacks Consensus Estimate of a $0.08 loss, and revenues of $53.23 million, exceeding estimates by 0.62%. The company's shares have gained approximately 18% year-to-date, outperforming the S&P 500. Currently, Cytek Biosciences holds a Zacks Rank #3 (Hold) as analysts anticipate further changes in estimates for the upcoming quarters.
Cytek Biosciences Q3 Earnings Call Highlights
Cytek Biosciences reported Q3 2026 revenue of $53.2 million, a 2% increase year-over-year, driven by strong U.S. demand and high-end instrument sales, despite weakness in Asia-Pacific. The company narrowed its full-year revenue guidance to $208 million to $211 million and expects adjusted EBITDA to be around break-even. Cytek also provided updates on its product pipeline, including the Borealis analyzer and Cytek Cloud, and discussed ongoing patent litigation where a jury largely found in its favor.
Revenue rose to $145.5M at Cytek Biosciences (CTKB), but its nine-month loss widened.
Cytek Biosciences (CTKB) reported increased revenue for both the third quarter and the first nine months of 2026, reaching $53.2 million and $145.5 million, respectively. However, the company's net loss widened to $37.1 million for the nine-month period, up from $22.5 million in the prior year, primarily due to higher litigation expenses and bad debt reserves. The company is also involved in ongoing patent litigation with Beckman Coulter, Inc., where a jury awarded $56.11 million in past damages against Cytek, though the judgment is not final.
Cytek Biosciences, Inc. (CTKB) Tops Q3 EPS by 1c ; Offers Guidance
Cytek Biosciences, Inc. (CTKB) reported Q3 EPS of ($0.05), surpassing analyst estimates by $0.01, and revenue of $53.2 million, which also beat the consensus. The company provided FY2026 revenue guidance in the range of $208-211 million, aligning with analyst expectations.
Cytek Beats On A Gross Margin Surge, But Slowing Growth And A Fading EBITDA Outlook Leave A Rallied Stock Little Room For Error
Cytek Biosciences (CTKB) reported a Q3 beat driven by improved gross margins due to manufacturing efficiencies, with GAAP gross margin reaching 59%. However, revenue growth decelerated significantly to 1.8%, and the adjusted EBITDA outlook for the full year has eroded to "around break-even." While the company showed strength in its U.S. academic franchise and high-end instruments, the stock's recent rally leaves little room for error given the trimmed guidance and reliance on a strong Q4.
Shared voting power tops 5% in Millennium’s amended Cytek Biosciences (CTKB) stake report.
Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, has filed an amended Schedule 13G/A report for Cytek Biosciences (CTKB), disclosing a 5.6% shared voting and dispositive power over 7,281,488 shares. Integrated Core Strategies (US) LLC also reported a 4.5% stake with 5,870,954 shares. The filing clarifies that the securities held by entities under Millennium's control should not be construed as an admission of beneficial ownership by Millennium or Mr. Englander.
What Cytek Biosciences Buyers Were Betting On
This article analyzes Cytek Biosciences' performance and what investors would have considered at the beginning of 2026. Despite a 28.0% return year-to-date, Q2 2026 results showed increased revenue but also a deeper net loss, challenging the bullish argument for future margin repair. The current share price of US$6.3 implies high expectations for recurring revenue expansion to offset rising costs and uneven funding.
Cytek Biosciences to Participate in Upcoming Investor Conferences
Cytek Biosciences, Inc. (Nasdaq: CTKB) announced its participation in two upcoming investor conferences. CFO William McCombe and Head of Investor Relations Mark Meehan will attend the UBS Global Healthcare Conference on November 9, 2026, while CEO Wenbin Jiang and CFO William McCombe will participate in a fireside chat at the Stephens Annual Investment Conference on November 17, 2026. Interested parties can access a webcast of the Stephens event on the company's investor relations website.
Cytek Biosciences (CTKB) Stock Sees Modest Fair Value Lift As Analysts Weigh Profitability
Analysts have adjusted their fair value estimates for Cytek Biosciences (CTKB) from approximately US$5.69 to US$6.17 per share, reflecting a moderate shift in price targets. While Stephens raised its price target to US$6 with an Overweight rating, Morgan Stanley maintained a more cautious Equal Weight rating with a US$5 target, indicating a mixed outlook on the stock's potential upside and profitability execution. The updated fair value incorporates revised assumptions for revenue growth, net profit margin, future P/E multiples, and discount rate.
Stephens Maintains Cytek Biosciences(CTKB.US) With Buy Rating, Raises Target Price to $6
Stephens has reiterated its Buy rating on Cytek Biosciences (CTKB.US). The firm also increased its price target for the company's stock to $6, indicating a positive outlook.
Cytek Biosciences, Inc. Estimates – NASDAQ:CTKB
This article provides an overview of Cytek Biosciences, Inc. (NASDAQ:CTKB) financials and analyst estimates on TradingView. It details how users can explore reported financial data and compare actual results with average, high, and low estimates across various financial statements and valuation metrics. The platform emphasizes that this information is not investment advice and encourages users to conduct their own research.
Cytek Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
Cytek Biosciences announced that it will release its third quarter 2026 financial results after market close on Wednesday, November 4, 2026. The company will also host a conference call and webcast to discuss these results, providing investors and stakeholders with an update on its financial performance and business operations.
Cytek Biosciences to report Q3FY26 results on November 4
Cytek Biosciences announced it will report its Q3 2026 financial results after market close on Wednesday, November 4, 2026. Management will host a conference call at 4:30 pm Eastern Time on the same day to discuss results, business developments, and the company's outlook. The company specializes in cell analysis solutions using its patented Full Spectrum Profiling (FSP) technology.
Total cash dividends paid of Cytek Biosciences, Inc. – NASDAQ:CTKB
The article provides information about Cytek Biosciences, Inc. (NASDAQ: CTKB) focusing on its total cash dividends paid. It appears to be a financial data point from TradingView, indicating no specific value or change percentage for the period mentioned.
Cytek Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
Cytek Biosciences (Nasdaq: CTKB) announced it will report its third-quarter 2026 financial results after market close on November 4, 2026. The company will also host a conference call on the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments, and outlook. A live audio webcast of the call will be available on the investors section of their website.
Cytek Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
Cytek Biosciences, Inc. (Nasdaq: CTKB) announced it will report its third-quarter 2026 financial results after market close on Wednesday, November 4, 2026. Management will host a conference call on the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss results, business developments, and outlook. A live audio webcast will be available on the company's investor relations website.
Cytek Biosciences stock gains 4.08 percent versus Tradegate close
Cytek Biosciences (CTKB) stock gained 4.08 percent against its Tradegate close on October 20, 2026, trading at EUR 4.85 at Lang & Schwarz. The company reported a 9.07 percent increase in second-quarter revenue to USD 48.14 million, exceeding analyst estimates, although it still recorded a diluted loss of USD 0.09 per share. Despite the gains in European trading, its Nasdaq price remains 12.08 percent below its 52-week high, with a market capitalization of USD 709.1 million.
A 1:30 p.m. Pacific call will cover Cytek's third-quarter results on Nov. 4.
Cytek Biosciences (Nasdaq: CTKB) announced it will report its third-quarter 2026 financial results after market close on November 4, 2026. Following the release, management will host a conference call at 1:30 p.m. Pacific / 4:30 p.m. Eastern to discuss the results, business developments, and future outlook. A live audio webcast will be available in the Investors section of the company's website.
Morgan Stanley keeps USD 5.00 target for Cytek Biosciences stock
Morgan Stanley has maintained its "Hold" rating and a USD 5.00 price target for Cytek Biosciences (CTKB) as of October 9, 2026. This target is slightly below the stock's last recorded price of USD 5.25 on October 16, 2026. The company's next earnings report is scheduled for November 11, 2026, following a second quarter where revenue beat analyst estimates but a net loss was reported.
Cytek Biosciences, Inc. (CTKB) Stock Forecasts
The article for Cytek Biosciences, Inc. (CTKB) stock forecasts encountered an error and could not retrieve data. It appears to be a placeholder or a failed attempt to load financial information from Yahoo Finance.
Six analysts put Cytek Biosciences stock at USD 5.56
Six analysts have set an average 12-month target of USD 5.56 for Cytek Biosciences (CTKB) stock as of October 13, 2026, which is 2.21 percent above its Nasdaq quote. The company reported second-quarter revenue of USD 48.14 million, exceeding consensus estimates, with a loss of USD 0.09 per share. Cytek's stock was trading at EUR 4.83 at Lang & Schwarz on October 15, 2026, and its next earnings date is estimated for November 4, 2026.
Cytek expanded Cloud Analysis. Cytek Biosciences stock traded at EUR 4.74 below EUR 4.77
Cytek Biosciences has expanded its Cytek Cloud platform with a new Cloud Analysis tool, broadening its workflow to include online data analysis and storage. The company reported better-than-expected revenue in Q2 2026 and introduced a Premium subscription tier to monetize its research base. Despite a slight intraday stock decline, analysts maintain a mixed rating with an average price target of USD 5.56.
Cytek Biosciences stock gets new shareholder voting rules
Cytek Biosciences (CTKB) has implemented new bylaws effective September 23, 2026, which tighten rules for shareholder proposals and director nominations, requiring more information and disclosure from proponents. This change follows the company's Q2 2026 revenue of $48.14 million, a 9.1% sequential increase, though it remained loss-making. Analysts have a "Hold" consensus on the stock, with an average price target of $5.56.
Cytek Biosciences stock fell 11.66 percent on October 6
Cytek Biosciences (CTKB) stock fell 11.66% on October 6, closing at USD 5.38 after an intraday high of USD 6.21. Despite a 6% revenue increase in Q2 2026 to USD 48.14 million, the company reported widening GAAP net losses of USD 12.2 million. Analysts maintain a cautious "Hold" consensus with an average price target of USD 5.56.
Cytek Biosciences (NASDAQ:CTKB) Updates Bylaws Following $56.1 Million Patent Verdict
Cytek Biosciences (NASDAQ:CTKB) recently updated its bylaws, a move that followed a $56.1 million patent infringement verdict against the company. The amendments include compliance with Rule 14a-19 universal proxy, new advance notice requirements for special meeting nominations, and expanded authority for the chairperson to reject non-compliant proposals. While the company stated no direct link between the verdict and the bylaw changes, investors are advised to monitor the outcomes of post-verdict motions and the impact of these new bylaws.
Cytek expands Cloud Analysis and Cytek Biosciences stock costs EUR 5.18
Cytek Biosciences has expanded its Cytek Cloud platform by introducing a new Cloud Analysis tool and a Premium subscription tier. The platform, which has over 28,000 users, allows researchers to import experimental data and perform analysis in the cloud, aiming to integrate a subscription feature into existing research workflows. Despite a 6% increase in Q2 2026 revenue to $48.10 million, the company reported an increased net loss of $12.20 million, although it raised the lower end of its full-year revenue guidance.
Cytek Biosciences Adopts Amended Bylaws Tightening Stockholder Nomination Rules
Cytek Biosciences, Inc. has amended its bylaws to tighten stockholder nomination and proposal rules, effective September 23, 2026. These changes are procedural governance updates aimed at modernizing the company's rules, rather than reflecting business or financial developments. The amendments include requirements for stockholders to provide additional information, certify share ownership, and comply with universal proxy rules, expanding the chairperson's authority to disregard non-compliant nominations.
Form 8K Cytek Biosciences Inc For: 29 September By Investing.com
This article announces that Cytek Biosciences Inc. has filed a Form 8K for September 29. The filing is brief, providing only the date and the company concerned, and includes its stock symbol CTKB with a recent performance percentage. The article is from Investing.com and was published on September 29, 2026.
Form 8K Cytek Biosciences Inc For: 29 September By Investing.com
This article reports on the filing of a Form 8K by Cytek Biosciences Inc. on September 29. The brief notice from Investing.com indicates this as a significant corporate event, providing the company's stock symbol CTKB and showing a slight positive change in its stock price. The article provides no further details regarding the content of the Form 8K.
Fund Divests Cytek Biosciences (CTKB) Following Revenue Slowdown and Declining Profitability
Brown Capital Management's Small Company Fund divested its holdings in Cytek Biosciences (CTKB) in Q2 2026 due to poor stock performance, slowing revenue growth, and declining profitability. The life sciences technology company, based in Fremont, California, faced pressure from a softer spending environment, budget constraints in life sciences tools, and increased competition. The fund noted that CTKB's growth and profitability profile had deteriorated since their initial investment, leading them to remove it from their portfolio in favor of AI stocks with greater upside potential.
Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool
Cytek Biosciences has expanded its Cytek Cloud digital ecosystem with a new Cloud Analysis tool, creating the industry's first end-to-end platform for flow cytometry. This tool integrates the entire workflow from panel design to data analysis, allowing researchers to seamlessly transition between experiment design, data acquisition, and analysis. The company also introduced a new Cytek Cloud Premium license, offering cloud-based data analysis and online storage.
Cytek introduces new end-to-end flow cytometry workflow
Cytek Biosciences has expanded its Cytek Cloud digital ecosystem with a new Cloud Analysis tool, integrating the entire flow cytometry workflow from panel design to data analysis into a single system. This innovation allows researchers to seamlessly move from experiment planning to data analysis, preserving experimental data and enabling direct import from SpectroFlo® desktop software. The platform, which supports Cytek Northern Lights™, Cytek Aurora®, Cytek Aurora® Evo, and Cytek Aurora® CS systems, also features an AI-powered SpectroPanel™ tool for automated fluorochrome assignment and offers various subscription tiers to meet different research needs.
Cytek Biosciences launches cloud-based analysis tool
Cytek Biosciences (NASDAQ:CTKB) has expanded its Cytek Cloud digital ecosystem by introducing a new Cloud Analysis tool. This new feature integrates the entire flow cytometry workflow, from panel design to data analysis, allowing researchers to access their work from various devices. The company is offering three subscription tiers for Cytek Cloud, with the Premium tier including the Cloud Analysis tool and online data storage, currently for U.S. customers.
A new tool lets researchers analyze cell data online without rebuilding their work
Cytek Biosciences (CTKB) has enhanced its Cytek Cloud platform with a new Cloud Analysis tool, allowing researchers to analyze experimental data online and access it from various devices without rebuilding their work. This addition integrates the entire flow cytometry workflow and introduces a Premium subscription tier that includes cloud-based analysis and online storage, currently available only in the U.S. The platform aims to provide a seamless research experience from panel design to data analysis, building on its existing suite of tools and growing user base.
Cytek Biosciences launches cloud-based analysis tool By Investing.com
Cytek Biosciences, Inc. (NASDAQ:CTKB) has expanded its Cytek Cloud digital ecosystem by launching a new Cloud Analysis tool. This addition integrates the flow cytometry workflow from panel design to data analysis, allowing researchers to import data and access their work from various devices. The company is offering three subscription tiers for Cytek Cloud, with the Cloud Analysis tool currently available to U.S. customers under the Premium tier.
Cytek Biosciences Expands Cytek Cloud with New Cloud Analysis Tool for End-to-End Flow Cytometry Workflow
Cytek Biosciences has expanded its Cytek Cloud digital ecosystem with a new Cloud Analysis tool, creating the industry's first end-to-end platform for flow cytometry workflows. This integration allows researchers to seamlessly move from panel design to data analysis, preserving experimental data and increasing efficiency. The platform now offers new subscription tiers, including Cytek Cloud Premium, which provides enhanced capabilities like cloud-based data analysis and online storage for U.S. customers.
Cytek Biosciences stock gains 2.25 percent near its yearly range
Cytek Biosciences (CTKB) stock gained 2.25 percent to USD 4.72 on September 21, 2026, reaching a market capitalization of USD 600.51 million. The stock's performance reflects market reaction, though no specific company-related reason for the move was identified in the available data. The article highlights the company's trading statistics and market valuation as key data points for investors.
Cytek Biosciences stock edges higher after recent earnings and analyst interest
Cytek Biosciences stock is trading in a tight range, with investors evaluating recent quarterly results and the company's growth outlook. While the stock is below its 52-week high, analysts see upside potential due to its differentiated technology in flow cytometry, balanced against execution risks and competitive pressures. The company's latest financials showed double-digit revenue growth and improving operating leverage, though net income remains modest due to continued investments.
Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?
The options market is showing high implied volatility for Cytek Biosciences (CTKB) stock, particularly for the October 16, 2026 $02.50 Put, suggesting investors anticipate a significant price movement. Despite this, analysts currently rate Cytek Biosciences as a Zacks Rank #3 (Hold), with recent estimate revisions indicating a move towards a break-even point for the current quarter. This discrepancy could signal a potential trading opportunity for options traders to sell premium.
Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?
The options market is showing high implied volatility for Cytek Biosciences (CTKB), particularly for the October 16, 2026 $2.50 Put, suggesting investors anticipate a significant price movement. Despite this, analysts currently rate Cytek Biosciences as a Zacks Rank #3 (Hold), with recent estimate revisions indicating a less optimistic fundamental outlook. This high implied volatility, coupled with analysts' cautious sentiment, might present a potential trading opportunity for those looking to sell premium.